All Elan articles
-
Business
Perrigo bags Elan and its bargain Irish tax rates
$8.6bn deal ends Elan’s takeover battle with Royalty Pharma
-
Business
Talk of a $6.6bn deal for Elan
Potential offer from Royalty Pharma comes as Elan ponders how to spend its cash from Tysabri rights
-
Business
Biogen buys Tysabri from Elan for $3.25bn
Elan earns huge cash injection for blockbuster drug
-
BusinessRecord insider trading case hits pharma
US authorities claim that hedge fund manager made illicit gains of $276 million in response to confidential clinical trial data
-
Business
Elan spins off drug discovery
The new company will be called Neotope Biosciences and focus on chronic degenerative diseases
-
Business
Bapineuzunab dropped
Development for the Alzheimer’s treatment stopped after clinical tests